syros pharmaceuticals news

Syros Pharmaceuticals Shares Plummet Premarket

Syros cut to neutral by H.C. Wainwright on failed drug study

H.C. Wainwright has downgraded Syros Pharmaceuticals (NASDAQ:SYRS) to neutral from buy, citing Tuesday’s announcement that a Phase 3 study of the company’s drug tamibarotene had failed to meet its primary endpoint.

YAHOO!Finance · 1d

Syros Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Syros Pharmaceuticals (SYRS) to Neutral from Buy with a price target of $1, down from $6, after the company announced that the Phase 3 SELECTMDS-1 trial, which evaluated tamibarotene combined with azacitidine for newly diagnosed,

MarketWatch · 2d

Syros Pharmaceuticals Shares Plummet Premarket After Study Failure

Shares of Syros Pharmaceuticals collapsed in premarket trading Wednesday after the biopharmaceutical company's lead asset, tamibarotene, failed in a late-stage study in a rare blood cancer.

Pieris Pharmaceuticals

Insider Monkey · 14d

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2024 Earnings Call Transcript

Operator: Good morning, and welcome to the Syros Pharmaceuticals Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

The Washington Post · 1d

Pieris Pharmaceuticals: Q3 Earnings Snapshot

Pieris Pharmaceuticals Inc. (PIRS) on Wednesday reported a loss of $2.9 million in its third quarter. On a per-share basis, the Boston-based company said it had a loss of $2.19. This story was generated by Automated Insights ( using data from Zacks Investment Research.

SFGate · 2h

Galmed Pharmaceuticals: Q3 Earnings Snapshot

(GLMD) on Thursday reported a loss of $1.9 million in its third quarter. The Ramat Gan, Israel-based company said it had a loss of $2.31 per share. This story was generated by Automated Insights ( using data from Zacks Investment Research.

Zacks.com on MSN1d

Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal

Shares of Syros Pharmaceuticals SYRS plunged 86.9% on Wednesday after a late-stage study of its only pipeline candidate, ...

Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default

Syros Pharmaceuticals' Phase 3 trial of tamibarotene in higher-risk myelodysplastic syndrome did not meet primary endpoints, ...

Yahoo Finance2d

Syros stock craters after lead cancer therapy flops in Phase III trial

Syros Pharmaceuticals’ stock has declined sharply for the second time in the past three months as a Phase III trial with ...

FierceBiotech2d

Syros flunks phase 3 blood cancer trial, triggering loan default and share-price plunge

Syros Pharmaceuticals’ blood cancer prospect tamibarotene has failed another study, triggering a default on a loan and ...

BioSpace2d

Syros Crashes Over 90% on Late-Stage MDS Fail, Loan Default

With the Phase III failure, Syros will discontinue the study of tamibarotene for myelodysplastic syndrome and will default on ...

Business Insider2d

Syros Pharmaceuticals (SYRS) was downgraded to a Hold Rating at TD Cowen

Syros Pharmaceuticals (SYRS – Research Report) received a Hold rating and price target from TD Cowen analyst Phil Nadeau yesterday. The company’s shares closed yesterday at $2.73. Nadeau covers ...

precisionmedicineonline1d

Syros Pharmaceuticals' Phase III Trial of Tamibarotene in MDS Fails to Meet Primary Endpoint

NEW YORK – Syros Pharmaceuticals said on Tuesday that its retinoic acid receptor-alpha agonist tamibarotene, which it was testing in combination with azacitidine in patients newly diagnosed with ...

TipRanks on MSN2d

Syros downgraded to Market Perform from Outperform at JMP Securities

JMP Securities analyst Jason Butler downgraded Syros Pharmaceuticals (SYRS) to Market Perform from Outperform without a price target The firm cites the “disappointing results” from the Phase 3 ...

Syros Stock - Investors of Syros Pharmaceuticals Encouraged to Contact Kehoe Law Firm, P.C. - SYRS

Philadelphia, Pennsylvania-- (Newsfile Corp. - November 13, 2024) - Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results